SIS Ventures

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

MiAlgae is a microalgae production company that provides microalgal products rich in omega-3 fatty acids, proteins, and antioxidants for livestock feeds. It aims to replace fishmeal in animal food, including aquaculture, by producing nutrients from algae rather than wild catch. The company emphasizes sustainability through circular economy practices and wastewater remediation to lower production costs and reduce environmental impact. Founded in 2016 and based in Edinburgh, United Kingdom, MiAlgae pursues scalable, seafood-free sources of essential nutrients for livestock feeds.

Solasta Bio develops environmentally friendly biological pesticides and insect control products. Its portfolio includes neuropeptide-based solutions that effectively manage resistant pests, enabling farmers to enhance crop production sustainably.

Metacarpal develops body-powered bionic hand prostheses, including a fully mechanical design with variable grips and grip lock to secure holds. The technology provides intuitive control similar to traditional body-powered devices and offers multiple grip options to adapt to different objects, with a focus on expanding access to prosthetic solutions in developing regions.

Nami Surgical specializes in developing and providing advanced robotic surgery technology. Their core offering is ultrasonic surgical tools designed to enhance the current robotic-assisted surgery market. By simplifying and making procedures safer, they expand the use of robots in surgeries requiring ultrasonic devices, thereby improving clinical outcomes and patient care. Their solutions provide surgeons with intuitive, high-performance, and maneuverable instruments for complex surgical tasks.

Nebu-Flow is a manufacturer focused on the development of advanced inhaled drugs aimed at patients with respiratory disorders. The company specializes in innovative pulmonary drug-delivery technology that allows for efficient administration of difficult-to-nebulize medications directly to the lungs. This includes existing formulations as well as emerging therapeutics such as biologics, nanomedicines, and vaccines. Nebu-Flow's technology is designed to control droplet size for optimal deep lung deposition, facilitating injection-free systemic drug delivery through inhalation. The company is dedicated to minimizing its environmental impact while ensuring the creation of a user-friendly and high-performing nebulizer for effective treatment of respiratory diseases.

Carcinotech is a pioneering company in cancer research, specializing in the manufacturing of 3D-printed micro-tumors derived from patient biopsies, primary cells, immune cells, and cancer stem cells. The company aims to enhance the drug screening process and facilitate pre-clinical and personalized medicine testing, ultimately accelerating the delivery of more effective cancer treatments to market. By employing advanced techniques in tissue engineering, robotic manufacturing, and stringent quality control, Carcinotech produces highly predictive, assay-ready printed tumors that reflect the heterogeneity of individual cancers. This innovative approach provides clinicians with models of "clinical biopsy" quality, significantly improving the accuracy of cancer treatment assessments. Collaborating with global partners, including leading pharmaceutical companies and medical professionals, Carcinotech is committed to transforming oncology drug development and increasing the likelihood of successful outcomes for cancer patients.

Founded in 2016, Trojan Energy specializes in providing electric vehicle charging infrastructure solutions worldwide. The company offers on-street flat and flush charging points, addressing the challenge faced by vehicle owners without off-street parking.

Beta Bugs specializes in insect genetics, developing high-performance Black Soldier Fly breeds for insect farmers. Headquartered at Easter Bush Campus, it collaborates with the Roslin Institute to enhance productivity in the insect protein sector.

Microplate Dx develops innovative diagnostic technology aimed at reducing fatalities caused by drug-resistant infections. The company, spun out from the University of Strathclyde in Glasgow, focuses on creating point-of-care solutions that accurately detect specific infections and enable optimal antibiotic prescribing within an hour.

Founded in 2008, Manus Neurodynamica specializes in medical diagnostic technologies for neuromotor impairments. Its primary product is a non-invasive device designed to support early diagnostics and monitoring of Parkinson's disease, with applications in academic research, pharmaceutical studies, and non-medical uses.

Solasta Bio develops environmentally friendly biological pesticides and insect control products. Its portfolio includes neuropeptide-based solutions that effectively manage resistant pests, enabling farmers to enhance crop production sustainably.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

MiAlgae is a microalgae production company that provides microalgal products rich in omega-3 fatty acids, proteins, and antioxidants for livestock feeds. It aims to replace fishmeal in animal food, including aquaculture, by producing nutrients from algae rather than wild catch. The company emphasizes sustainability through circular economy practices and wastewater remediation to lower production costs and reduce environmental impact. Founded in 2016 and based in Edinburgh, United Kingdom, MiAlgae pursues scalable, seafood-free sources of essential nutrients for livestock feeds.

Nebu-Flow is a manufacturer focused on the development of advanced inhaled drugs aimed at patients with respiratory disorders. The company specializes in innovative pulmonary drug-delivery technology that allows for efficient administration of difficult-to-nebulize medications directly to the lungs. This includes existing formulations as well as emerging therapeutics such as biologics, nanomedicines, and vaccines. Nebu-Flow's technology is designed to control droplet size for optimal deep lung deposition, facilitating injection-free systemic drug delivery through inhalation. The company is dedicated to minimizing its environmental impact while ensuring the creation of a user-friendly and high-performing nebulizer for effective treatment of respiratory diseases.

Carcinotech is a pioneering company in cancer research, specializing in the manufacturing of 3D-printed micro-tumors derived from patient biopsies, primary cells, immune cells, and cancer stem cells. The company aims to enhance the drug screening process and facilitate pre-clinical and personalized medicine testing, ultimately accelerating the delivery of more effective cancer treatments to market. By employing advanced techniques in tissue engineering, robotic manufacturing, and stringent quality control, Carcinotech produces highly predictive, assay-ready printed tumors that reflect the heterogeneity of individual cancers. This innovative approach provides clinicians with models of "clinical biopsy" quality, significantly improving the accuracy of cancer treatment assessments. Collaborating with global partners, including leading pharmaceutical companies and medical professionals, Carcinotech is committed to transforming oncology drug development and increasing the likelihood of successful outcomes for cancer patients.

Good-Loop is an advertising platform that converts ad spend into charitable funding. It runs video ads across a network of quality online publishers and uses an opt-in model where users who choose to watch an advertisement have 50% of the advertiser revenue donated to a social cause of their choice. This approach is positioned as more engaging and ethically aligned, with completed view rates reported at 61%—well above typical YouTube completion rates of around 30% for the same ads. The company aims to provide a positive experience for audiences and a meaningful channel for brands to support causes. Good-Loop participated in the Collider Startup Accelerator in 2017.

Talking Medicines Limited is a data technology company based in Glasgow, United Kingdom, that focuses on capturing and structuring the global voice of patients regarding launched medicines. The company offers Medsmart, an application that collects comprehensive data about medication adherence, including how, why, and what patients are taking. Its services include PatientMetRx®, a social intelligence platform that employs artificial intelligence and natural language processing to transform unstructured feedback from patients into actionable insights for pharmaceutical companies. This platform allows clients to utilize large language models to access curated patient and healthcare professional experiences, thereby enabling data-driven decision-making. Talking Medicines also provides a real-world persona data service with monthly updates, digital focus groups for surveys and questionnaires, and custom solutions tailored to specific pharmaceutical needs. Established in 2013 and rebranded in December 2015, the company serves the pharmaceutical and healthcare sectors, aiming to enhance marketing effectiveness and improve patient health outcomes through advanced patient insights.

Founded in 2016, Trojan Energy specializes in providing electric vehicle charging infrastructure solutions worldwide. The company offers on-street flat and flush charging points, addressing the challenge faced by vehicle owners without off-street parking.

EnteroBiotix develops orally available microbial therapeutics derived from human gastrointestinal tract bacteria. Its focus is preventing and treating diseases by restoring gut microbiota balance.

Founded in 2016, Trojan Energy specializes in providing electric vehicle charging infrastructure solutions worldwide. The company offers on-street flat and flush charging points, addressing the challenge faced by vehicle owners without off-street parking.

Solasta Bio develops environmentally friendly biological pesticides and insect control products. Its portfolio includes neuropeptide-based solutions that effectively manage resistant pests, enabling farmers to enhance crop production sustainably.

Cyan Forensics specializes in developing advanced technologies aimed at assisting law enforcement agencies, social media platforms, and cloud service providers. Their solutions are designed to detect and prevent the dissemination of harmful content, including material related to paedophilia and terrorism. The company's innovations significantly reduce the time required for police to examine consumer devices, thereby enhancing the efficiency of investigations.

Founded in 2008, Manus Neurodynamica specializes in medical diagnostic technologies for neuromotor impairments. Its primary product is a non-invasive device designed to support early diagnostics and monitoring of Parkinson's disease, with applications in academic research, pharmaceutical studies, and non-medical uses.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Founded in 2016, Trojan Energy specializes in providing electric vehicle charging infrastructure solutions worldwide. The company offers on-street flat and flush charging points, addressing the challenge faced by vehicle owners without off-street parking.

Cyan Forensics specializes in developing advanced technologies aimed at assisting law enforcement agencies, social media platforms, and cloud service providers. Their solutions are designed to detect and prevent the dissemination of harmful content, including material related to paedophilia and terrorism. The company's innovations significantly reduce the time required for police to examine consumer devices, thereby enhancing the efficiency of investigations.

EnteroBiotix develops orally available microbial therapeutics derived from human gastrointestinal tract bacteria. Its focus is preventing and treating diseases by restoring gut microbiota balance.

Talking Medicines Limited is a data technology company based in Glasgow, United Kingdom, that focuses on capturing and structuring the global voice of patients regarding launched medicines. The company offers Medsmart, an application that collects comprehensive data about medication adherence, including how, why, and what patients are taking. Its services include PatientMetRx®, a social intelligence platform that employs artificial intelligence and natural language processing to transform unstructured feedback from patients into actionable insights for pharmaceutical companies. This platform allows clients to utilize large language models to access curated patient and healthcare professional experiences, thereby enabling data-driven decision-making. Talking Medicines also provides a real-world persona data service with monthly updates, digital focus groups for surveys and questionnaires, and custom solutions tailored to specific pharmaceutical needs. Established in 2013 and rebranded in December 2015, the company serves the pharmaceutical and healthcare sectors, aiming to enhance marketing effectiveness and improve patient health outcomes through advanced patient insights.